With this first post since the holidays, there is so much to discuss, yet so little firm ground on which to anchor the discussion. Since December 23, the Trump administration has added two more drug pricing reform models to the gordian knot of US pharmaceutical reimbursement, and authors from the University of Washington School of … Continue reading The Next Set of Biologics for Medicare Price Negotiations Predicted (and Eliminated?)